DOCSLIB.ORG

Mid-Level Practitioners Authorization by State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Mid-Level Practitioners Authorization by State Pursuant to Title 21, Code of Federal Regulations, Section 1300.01(b28), the term mid-level practitioner means an individual practitioner, other than a physician, dentist, veterinarian, or podiatrist, who is licensed, registered, or otherwise permitted by the United States or the jurisdiction in which he/she practices, to dispense a controlled substance in the course of professional practice. Examples of mid-level practitioners include, but are not limited to, health care providers such as nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists and physician assistants who are authorized to dispense controlled substances by the state in which they practice. AMB Ambulance Service AS Animal Shelters CC Certified Chiropractor DOM Doctors of Oriental Medicine ET Euthanasia Technicians HMD Homeopathic Physician MP Medical Psychologists ND Naturopathic Physician NH Nursing Homes NP Nurse Practitioners OD Optometrists PA Physician Assistants RPH Registered Pharmacists Table Description The table represents the controlled substances authority for Mid-level Practitioner's by discipline within the state of which they practice. It indicates the categories of Mid-Level Practitioners by State and the licensing authority granted to each category within that particular State through the Drug Enforcement Administration (DEA). If authority is granted, specific schedules are listed along with any special instructions like administer only, dispense only or order only. It may also indicate if the DEA is reviewing a new law to see if it is in fact consistent with the issuance of a DEA registration for controlled substances. If authority is NOT granted for a particular category, a "NO" will be indicated. The Drugs and drug products that come under the Controlled Substances Act are divided into five schedules. Some examples in each schedule are outlined below. Schedule I substances (1) The substances in this schedule are those that have no accepted medical use in the United States and have a high abuse potential. Some examples are heroin, marihuana, LSD, MDMA, peyote. Schedule II/IIN substances (2/2N) The substances in this schedule have a high abuse potential with severe psychic or physical dependence liability. Schedule II controlled substances consist of certain narcotic, stimulant and depressant drugs. Examples of Schedule II narcotic controlled substances are: opium, morphine, codeine, hydromorphone (Dilaudid), methadone, pantopon, meperidine (Demerol), and hydrocodone (Vicodin®). Examples of Schedule IIN non-narcotic would be Amphetamine, Methamphetamine, Nabilone. Schedule III/IIIN substances (3/3N) The substances listed in this schedule have an abuse potential less than those in Schedules I and II, and include compounds containing limited quantities of certain narcotic drugs (Schedule 3) and non-narcotic drugs (Schedule 3N) such as: codeine (Tylenol with Codeine), derivatives of babituric acid except those listed in another schedule, nalorphine, benzphetamine, chlorphentermine, clortemine, phendimetrazine, paregoric and any compound, mixture, preparation or suppository dosage form containing amobarbital, secobarbital or pentobarbital. Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®). Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone. Schedule IV substances (4) The substances in this schedule have an abuse potential less than those listed in Schedule III and include such drugs as: barbital, phenobarbital, chloral hydtrate, clorazepate (Tranxene), alprazolam (Xanax), Quazepam (Dormalin). Schedule V substances (5) The substances in this schedule have an abuse potential less than those listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotic and stimulant drugs generally for antitussive, antidiarrheal and analgesic purposes. Some examples are buprenorphine and propylhexedrine. Table Key 2, 2N, 3, 3N, 4, 5 Schedule categories Rx's Prescriptions CRNA Certified Registered Nurse Anesthetists CNM Certified Nurse Midwives Per formulary Per the directives written out by the state licensing board. MID LEVEL PRACTITIONERS - Controlled Substance Authority by Discipline within State Last Updated: 9/24/2021 STATE AMB AS CC DOM ET HMD MP ND NH NP OD PA RPH Ambulance Service Animal Shelters Certified Doctors of Oriental Euthanasia Homeopathic Medical Naturopathic Nursing Homes Nurse Practitioners Optometrists Physician Registered Chiropractor Medicine Technicians Physician Psychologist Physician Assistants Pharmacists Alabama NO 2N & 3N Sodium NO NO NO NO NO NO NO 2,2N,3, 3N, 4, 5 3, 3N, 4, 5 2,2N,3, 3N, 4, 5 NO Pentobarbital & Administer & Administer & Prescribe, Sodium Prescribe Only. Prescribe Dispense & Pentobarbital Special permit for Administer. W/Lidocaine 2/2N Special permit Line 1 Animal for 2/2N Shelter Line 2 ET's Name administer / procure Alaska NO 2N & 3N Sodium NO NO 2N & 3N NO NO NO NO 2, 2N, 3, 3N, 4, 5 3, 4, 5 2, 2N, 3, 3N, 4, 5 NO Pentobarbital & Administer Only Prescribe, Prescribe Prescribe, Sodium Dispense, Prescribe 2 Only Administer & Pentobarbital Administer, for Hydrocodone Dispense, W/Lidocaine procure Products Procure Line 1 Animal Shelter Line 2 ET'S Name administer / procure Arizona NO 2N & 3N Only Law NO NO NO 2, 2N, 3, 3N, 4, 5 NO 2, 3, 3N, 4, 5 NO 2, 2N, 3, 3N, 4, 5 3, 3N Prescribe, 2, 2N, 3, 3N, 4, 5 NO Enforcement or Prescribe, Prescribe, Prescribe, Order, Dispense, Procurement City Animal Shelter Dispense, Dispense, Administer, Administer limited to administer / Administer Administer, procure Prescribe 2 Only samples only procure procure for Hydrocodone Products 1 of 11 MID LEVEL PRACTITIONERS - Controlled Substance Authority by Discipline within State Last Updated: 9/24/2021 STATE AMB AS CC DOM ET HMD MP ND NH NP OD PA RPH Arkansas NO 2N & 3N NO NO NO NO NO NO NO 3,3N,4,5 APRNs 3, 3N, 4, 5 3, 3N, 4 & 5 NO Line 1 Animal Administer, Order, Prescribe 2 Only Administer, Shelter Line 2 ET'S Prescribe 2 for for Hydrocodone Order Name administer Hydrocodone Products Prescribe 2 for / procure Products Only Hydrocodone with a Combination Collaborative Products Only Practice with a signed Agreement. May Protocol on file be extended to C2 and C2N drugs if in accordance with Arkansas Act 593 California NO NO NO NO 2N FOR Sodium NO NO 3, 3N, 4 & 5 NO 2, 2N, 3, 3N, 4, 5 2, 3, & 4 2, 2N, 3, 3N, 4, 5 2, 2N, 3, 3N, 4, 5 Pentobarbital Prescribe Only Prescribe, Prescribe Only Prescribe, Prescribe Only ONLY Dispense, for Hydrocodone, Dispense, Line 1 RVT Line 2 Administer Codeine, & Administer Shelter NOTE: 2 Requires Tramadol Only (3 administer / Continuing day Rx only) procure Education Colorado 2, 2N, 3, 3N, 4, 5 2N & 3N Only Law NO NO NO NO NO NO NO Prescribe 2, 2N, 3, Prescribe Only 3, Prescribe & NO Line 1 AMB Line Enforcement or 3N, 4, 5 3N, 4, 5 Dispense 2, 2N, 2 DR's Name/ City Animal Shelter May Dispense & Prescribe 2 Only 3, 3N, 4, 5 Administer, administer / Administer for Hydrocodone Dispense and procure Samples Products Procure CRNA's/APN's may procure Connecticut NO NO NO NO NO NO NO NO NO 2, 2N, 3, 3N, 4, 5 2, 2N, 3, 3N, 4, 5 2, 2N, 3, 3N, 4, 5 NO Prescribe, Prescribe, Prescribe, Dispense, Dispense, Dispense, Administer, Administer Administer, procure procure 2 of 11 MID LEVEL PRACTITIONERS - Controlled Substance Authority by Discipline within State Last Updated: 9/24/2021 STATE AMB AS CC DOM ET HMD MP ND NH NP OD PA RPH Delaware NO NO NO NO NO NO NO NO NO 2, 2N, 3, 3N, 4, 5 3, 4, 5 Prescribe 2, 2N, NO Prescribe, Prescribe 3, 3N, 4, 5 May Administer & Prescribe 2 Only Administer & Dispense, procure for Hydrocodone Dispense Products Samples 72 hour supply District of 2, 2N, 3, 3N, 4, 5 NO NO NO NO NO NO 3N for NO 2, 2N, 3, 3N, 4, 5 NO 2, 2N, 3, 3N, 4, 5 NO Columbia Administer, Testosterone Prescribe Only Prescribe, Dispense and Only Prescribe, Dispense & Procure Administer & Procure Dispense, Florida NO 2N, 3N, Sodium NO NO NO NO NO NO NO 2, 2N, 3, 3N, 4, 5 3, 4 Administer, 2, 2N, 3, 3N, 4, 5 NO Pentobarbital & Prescribe, Prescribe only Prescribe, Sodium Administer & (APAP Administer & Pentobarbital Dispense only in W/Codeine & Dispense only in w/Lidocaine accordance with Tramadol) accordance with administer / state law Requires 20 hrs. state law procure CME Georgia NO NO NO NO NO NO NO NO NO 3, 3N, 4, 5 3, 3N, 4 3, 3N, 4 & 5 NO Prescribe, Prescribe 2 Only Prescribe Only Administer & for Hydrocodone Dispense Products Guam (TT) NO 2N & 3N NO NO 2N & 3N NO NO NO NO APRN's can NO 4 & 5 Only NO administer / administer Prescribe Prescribe, procure 2, 2N, 3, 3N, 4, 5 Dispense & Administer Hawaii 2, 2N, 3, 3N, 4, 5 NO NO NO NO NO NO NO 2, 2N, 3, 3N, 4, 5 2.2n,3,3N,4,5 NO 3, 3N, 4 & 5 NO LINE 2 DR'S Administer & Prescribe, NAME Prescribe Dispense, Administer, Administer Dispense and May Write Procure Orders for Inpatients for 2-5 3 of 11 MID LEVEL PRACTITIONERS - Controlled Substance Authority by Discipline within State Last Updated: 9/24/2021 STATE AMB AS CC DOM ET HMD MP ND NH NP OD PA RPH Idaho 2, 2N, 3, 3N, 4, 5 2N, 3, 3N, 4 NO NO NO NO 2N, 3N, 4, 5 NO NO 2, 2N, 3, 3N, 4, 5 2, 2N, 3, 3N, 4, 5 2, 2N, 3, 3N, 4, 5 2, 2N, 3, 3N, 4, 5 Administer, Administer & Prescribe Only Prescribe, Prescribe, Prescribe per Administer, Dispense and Procure Only Administer & Administer & Board Prescribe & Procure Dispense, procure Dispense authorization Dispense and per (pursuant to prescriptive collaborative practice of agreement with supervising prescriber) physician. Can administer and dispense per Delegation of Service agreement.
Recommended publications
  • Palliative Care Case of the Month

    Palliative Care Case of the Month

    PALLIATIVE CARE CASE OF THE MONTH “Treating Non-Infectious Diarrhea” by Robert Arnold, MD Volume 19, No. 98 August, 2019 Case 1: Mr. Jones is a 58-year-old man with short gut Three drugs are used because of their ability to slow down the syndrome. Palliative Care was consulted for goals of care, gut, allowing for more time for absorption of intestinal fluids a however quickly it became clear uncontrolled diarrhea was a decrease of diarrhea. The most well-know is loperamide, a larger priority. He said having to change the bag every few hours synthetic opiate which has minimal absorption. The dosing is 4 completely interfered with his living a normal life. He said, “I’d mg after one’s first bowel movement and then 2 mg after every rather die than have all of this diarrhea.” unformed stool, up to 16 mg (in palliative care patients there is some data for use up to 54 mg).9, 10 Loperamide should be Case 2: A 62-year-old woman with non-small cell lung cancer continued for 12 hours after diarrhea is stopped. Adverse effects is receiving immunotherapy. She has done quite well but is include mostly constipation, abdominal cramps, nausea and distressed by her diarrhea. She tried Lomotil and Imodium but rarely CNS effects like fatigue or dizziness. Cases of torsades de neither worked. When seeing her palliative care doctor, she said, pointes and death have been reported with higher than “It isn’t worth treating my cancer if I can’t live a normal life.” 9 recommended doses.
  • CSAS Narcotic Treatment Service for Opiate Addiction Initial Certification

    CSAS Narcotic Treatment Service for Opiate Addiction Initial Certification

    DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN Division of Quality Assurance Page 1 of 16 F-00538 (11/11) COMMUNITY SUBSTANCE ABUSE SERVICE (CSAS) NARCOTIC TREATMENT SERVICE FOR OPIATE ADDICTION INITIAL CERTIFICATION APPLICATION Chapter DHS 75.15 Initial Certification • Initial certification must meet all requirements, including staffing requirements (hired and in place) before services begin. • This document paraphrases the rule language for application purposes. • Applicants for a new narcotic treatment service for opiate addiction must demonstrate preparedness to comply with all Chapter DHS 75.15 standards. Applicants will have completed all required policies, including Chapter DHS 94 (Patient Rights). Use the check boxes ( ) to affirm readiness to meet standards. • ATTENTION: The clinic must contact the regional Health Services Specialist to arrange a site visit following the submission of fee and this application. Chapter DHS 75.01(1) Authority and Purpose This application is promulgated under the authority of ss. 46.973(2)(c), 51.42(7)(b), and 51.45(8) and (9), Wis. Stats., to establish standards for community substance abuse prevention and treatment services under ss. 51.42 and 51.45, Wis. Stats. Sections 51.42(1) and 51.45(1) and (7) provide that a full continuum of substance abuse services be available to Wisconsin citizens from county departments of community programs, either directly or through written agreements or contracts that document the availability of services. This application provides that service recommendations for initial placement, continued stay, level of care transfer, and discharge of a patient be made through the use of Wisconsin uniform placement criteria (WI- UPC), American Society of Addiction Medicine (ASAM) placement criteria, or similar placement criteria that may be approved by the department.
  • Anti-Diarrheal Activity and Brine Shrimp Lethality Bioassay of Methanolic Extract of Cordyline Fruticosa (L.) A

    Anti-Diarrheal Activity and Brine Shrimp Lethality Bioassay of Methanolic Extract of Cordyline Fruticosa (L.) A

    Naher et al. Clinical Phytoscience (2019) 5:15 https://doi.org/10.1186/s40816-019-0109-z ORIGINAL CONTRIBUTION Open Access Anti-diarrheal activity and brine shrimp lethality bioassay of methanolic extract of Cordyline fruticosa (L.) A. Chev. leaves Sharmin Naher1*, Md. Abdullah Aziz1, Mst. Irin Akter2, S. M. Mushiur Rahman1, Sadiur Rahman Sajon1 and Kishor Mazumder1,3 Abstract Background: Cordyline fruticosa (L.) A. Chev. (Asparagaceae) is a plant which is traditionally used for the treatment of cough, bloody cough, diarrhea, dysentery, high fever, difficulties in urine, bloody urine, small pox, madness, skin eruptions, joint pains, rheumatic bone pains, sore throat, neck pain, bleeding hemorrhoids and inflammation in the digestive tract. Therefore, the present work aims to investigate the antidiarrheal and cytotoxic activities of methanolic extract of Cordyline fruticosa leaves in mice and brine shrimp, respectively. Methods: The effects of the methanol extract of Cordyline fruticosa leaves (MCFL) on castor oil-induced diarrhea, magnesium sulphate induced diarrhea and charcoal meal test in mice were investigated. In addition, brine shrimp lethality bioassay method was used to evaluate cytotoxic activity of MCFL. Results: In castor oil induced diarrheal test, MCFL at the dose of 200, 400 and 800 mg/kg body weight significantly (∗P< 0.05, versus control) and dose-dependently reduced the frequency of diarrhea. The frequency of magnesium sulphate-induced diarrhea was significantly reduced by MCFL at the dose of with 800 mg/kg. In the charcoal meal test, the extract at the dose of 400 and 800 mg/kg body weight significantly (∗P< 0.05) reduced the distance travelled by charcoal along the intestinal tract when compare with control.
  • Preventing Alcohol and Other Drug Use in Student-Athletes

    Preventing Alcohol and Other Drug Use in Student-Athletes

    Preventing Alcohol and Other Drug Use in Student-Athletes Most Student-Athletes Alcohol Use Don’t Use/Misuse Most don’t misuse alcohol. See percentages of higher risk drinking within the last 12 months.* % of student-athletes reporting “never used” PERCENTAGES OF ALCOHOL USE EFFECTS ON ATHLETIC PERFORMANCE BASED ON AMOUNT 99.6% Heroin • Constricts aerobic metabolism and endurance 99.5% Methamphetamine Division I Division II Division III • Requires increased work to maintain 1.0% 1.6% 1.8% weight 99.1% Anabolic steroids Female • Inhibits absorption of nutrients, More than which then: 98.2% Ultracet, Ultram or Tramadol 4 drinks 38.9% 33.1% 41.2% - Reduces endurance 98.0% Amphetamines 10+ drinks - Decreases protein synthesis for muscle fiber repair 97.4% Human growth hormone (HGH) - Decreases immune response 97.3% Injectable Toradol - Increases risk of injury Male 10.7% 11.5% 15.8% • Alcohol use 24 hours before athletic 97.1% LSD More than activity significantly reduces aerobic 5 drinks 39.0% 38.6% 51.8% performance 96.1% Ecstacy/Molly 10+ drinks • Weekly alcohol consumption 94.5% Cocaine doubles the rate of injury 84.5% ADHD stimulants WITHIN THE 18.2% say they did not drink EFFECTS OF A HANGOVER 83.3% Narcotic pain medication within the last year LAST YEAR, • Increases heart rate HAVE YOU 75.3 % Marijuana • Decreases left ventricular performance EXPERIENCED A • Increases blood pressure 49.0% Tylenol or acetaminophen HANGOVER AS • Decreases endurance performance A CONSEQUENCE • Dehydration 44.6% NSAIDs OF DRINKING ALCOHOL? No: Yes: 19.8% Alcohol 29.8% 52% Marijuana Use Stimulant Use Narcotic Use Most don’t use marijuana.
  • The Opioid Epidemic: What Labs Have to Do with It?

    The Opioid Epidemic: What Labs Have to Do with It?

    The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 1 Analysis. Answers. Action. www.aphl.org Opioid overdose crisis 2 Analysis. Answers. Action. www.aphl.org Opiates and Opioids • Opiates vs. Opioids • Opiates: Naturally occurring, derived from the poppy plant • Opioids: “Opiate-like” drugs in effects, not chemical structure Includes opiates • Narcotic analgesics • CNS depressants • DEA Schedule I or II controlled substances • Additive effect with other CNS depressant drugs Analysis. Answers. Action. www.aphl.org Efficacy of Opioids • How do opioids work? • Bind with opioid receptors • Brain, spinal cord, GI tract, and throughout the body • Pain, emotion, breathing, movement, and digestion Opioid Receptor Analysis. Answers. Action. www.aphl.org Effects of Opioids Physiological Psychological • Pain relief • Drowsiness/ sedation • Cough suppression • Mental confusion • GI motility • Loss of memory • Respiratory depression • Lethargy/ apathy • Pupillary constriction • Euphoria/ tranquility • Itching • Mood swings • Constipation • Depression • Dependence • Withdrawal • Dependence Analysis. Answers. Action. www.aphl.org Opiates 1 Opiates • Naturally occurring alkaloids Opium • Latex from the opium poppy plant Codeine: • Mild to moderate pain • Antitussive Morphine: • Severe pain • Metabolite of codeine and heroin Analysis. Answers. Action. www.aphl.org Opiates 2 Semi-synthetic Opiates: • Synthesized from a natural opiate Heroin: • Schedule I narcotic Hydrocodone (Vicodin): • Mild to moderate pain • Metabolizes to hydromorphone (Dilaudid) Oxycodone (Oxycontin/Percocet): • Moderate to severe pain • Metabolizes to oxymorphone (Opana) Analysis. Answers. Action.
  • Legalization of the Non-Medical Use of Drugs Is Presented Below

    Legalization of the Non-Medical Use of Drugs Is Presented Below

    I. OVERVIEW 1. Measures taken nationally and internationally to reduce drug abuse and trafficking have yet to yield more universally visible and decisive results and, consequently, the validity and appropriateness of the drug control measures that Governments have agreed upon in international conventions and resolutions have continued to be questioned. The drug abuse and trafficking situation, which is accompanied by violence and corruption, remains grim, but the International Narcotics Control Board is not convinced that valid alternatives to present policies have been found that would meaningfully reverse the situation. Worldwide efforts to combat drug abuse and trafficking have to be continuous, balanced and in an internationally concerted manner in order for further positive results to be achieved. Drug abuse is closely linked to political, social and economic problems, and progress in these areas will undeniably contribute to the solution of the drug abuse problem. In a number of countries positive developments have been reported and these should be more carefully studied and discussed so that successful experiences in one country can be considered by others. In addition, the mass media are invited to analyse and report on such positive developments. 2. The efforts of the United Nations International Drug Control Programme (UNDCP) are highly appreciated by the Board. During 1992, UNDCP cooperated with 97 countries through 130 regional and country-specific drug control programmes. In addition, the operational work programme for 1992 included 30 global projects supporting a broad range of drug control activities, such as specialized training, research and advisory services. These activities have been implemented by UNDCP in collaboration with various specialized agencies of the United Nations system, other international organizations and various non-governmental organizations.
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L

    A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L

    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
  • Genl:VE 1970 © World Health Organization 1970

    Genl:VE 1970 © World Health Organization 1970

    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
  • Definition of Controlled Substance Schedules

    Definition of Controlled Substance Schedules

    UPDATED MARCH 2018 DEFINITION OF CONTROLLED SUBSTANCE SCHEDULES Drugs and other substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the U.S., their relative abuse potential, and likelihood of causing dependence when abused. Examples of the drugs in each schedule are listed below. Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4- methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. 1 Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
  • Synthetic Drugs: Overview and Issues for Congress

    Synthetic Drugs: Overview and Issues for Congress

    Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700 www.crs.gov R42066 Synthetic Drugs: Overview and Issues for Congress Summary Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. From 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as “K2” and “Spice”) and stimulants (such as “bath salts”) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Opioid Receptorsreceptors

    Opioid Receptorsreceptors

    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.